ENXTPA:ABPharmaceuticals
Here's What AB Science S.A.'s (EPA:AB) Shareholder Ownership Structure Looks Like
A look at the shareholders of AB Science S.A. ( EPA:AB ) can tell us which group is most powerful. Institutions will...
ENXTPA:BOIPharmaceuticals
Private companies invested in Boiron SA (EPA:BOI) copped the brunt of last week's €54m market cap decline
To get a sense of who is truly in control of Boiron SA ( EPA:BOI ), it is important to understand the ownership...
ENXTPA:IPNPharmaceuticals
Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 50% Undervaluation?
Today we will run through one way of estimating the intrinsic value of Ipsen S.A. ( EPA:IPN ) by taking the expected...
ENXTPA:BOIPharmaceuticals
Estimating The Intrinsic Value Of Boiron SA (EPA:BOI)
In this article we are going to estimate the intrinsic value of Boiron SA ( EPA:BOI ) by estimating the company's...
ENXTPA:MEDCLPharmaceuticals
Individual investors who have a significant stake must be disappointed along with institutions after MedinCell S.A.'s (EPA:MEDCL) market cap dropped by €29m
A look at the shareholders of MedinCell S.A. ( EPA:MEDCL ) can tell us which group is most powerful. With 46% stake...
ENXTPA:VIRPPharmaceuticals
Here's Why I Think Virbac (EPA:VIRP) Is An Interesting Stock
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
ENXTPA:BOIPharmaceuticals
Boiron (EPA:BOI) sheds €49m, company earnings and investor returns have been trending downwards for past five years
Generally speaking long term investing is the way to go. But along the way some stocks are going to perform badly. For...
ENXTPA:ALDVIPharmaceuticals
Investors in Advicenne (EPA:ADVIC) from a year ago are still down 28%, even after 16% gain this past week
This week we saw the Advicenne S.A. ( EPA:ADVIC ) share price climb by 16%. But that is minimal compensation for the...
ENXTPA:VETOPharmaceuticals
Is Vetoquinol (EPA:VETO) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...